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Abstract
Background/Aims: Vascular calcification represents a huge clinical problem contributing to 
adverse cardiovascular events, with no effective treatment currently available. Upregulation 
of hepatocyte growth factor has been linked with vascular calcification, and thus, represent 
a potential target in the development of a novel therapeutic strategy. Glycomimetics have 
been shown to interrupt HGF-receptor signalling, therefore this study investigated the effect 
of novel glycomimetics on osteogenic signalling and vascular calcification in vitro. Methods: 
Primary human vascular smooth muscle cells (HVSMCs) were induced by β-glycerophosphate 
(β-GP) and treated with 4 glycomimetic compounds (C1-C4). The effect of β-GP and C1-C4 
on alkaline phosphatase (ALP), osteogenic markers and c-Met/Notch3/HES1 signalling was 
determined using colorimetric assays, qRT-PCR and western blotting respectively. Results: 
C1-C4 significantly attenuated β-GP-induced calcification, as shown by Alizarin Red S staining 
and calcium content by day 14. In addition, C1-C4 reduced ALP activity and prevented 
upregulation of the osteogenic markers, BMP-2, Runx2, Msx2 and OPN. Furthermore, β-GP 
increased c-Met phosphorylation at day 21, an effect ameliorated by C2 and C4 and the c-Met 
inhibitor, crizotinib. We next interrogated the effects of the Notch inhibitor DAPT and confirmed 
an inhibition of β-GP up-regulated Notch3 protein by C2, DAPT and crizotinib compared to 
controls. Hes-1 protein upregulation by β-GP, was also significantly downregulated by C2 and 
DAPT. GOLD docking analysis identified a potential binding interaction of C1-C4 to HGF which 
will be investigated further. Conclusion: These findings demonstrate that glycomimetics have 
potent anti-calcification properties acting via HGF/c-Met and Notch signalling.
Dr Fiona Wilkinson Faculty of Science & Engineering, Dept. of Life Sciences, Centre for Bioscience,
Manchester Metropolitan University, John Dalton Building, Chester Street, Manchester, M15GD (UK)
Tel. +44 161 247 3349, E-Mail F.Wilkinson@mmu.ac.uk
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Introduction
Vascular calcification is an active and highly regulated process of abnormal mineralisation 
of the vessel wall and is a key risk factor for adverse cardiovascular events [1]. There is a 
particularly high prevalence of vascular calcification in patients with diabetes and chronic 
kidney disease (CKD) [2, 3]. When vascular calcification is localised to atherosclerotic 
plaques, it occurs as microcalcifications, which could represent an early stage of the process, 
that may progress to larger calcified blocks [4-6].
Bone morphogenetic protein-2 (BMP-2) and other bone matrix proteins, including 
osteocalcin, osteopontin (OPN) and osteonectin have been identified within the vicinity 
of vascular calcification [7]. BMP-2 is a member of the transforming growth factor-β 
superfamily [8] associated with osteoblast differentiation and bone formation [7]. Reports 
suggest the effects of BMP-2 are executed by upregulating Runt-related transcription factor-2 
(Runx2) [9] and alkaline phosphatase (ALP) expression and activity [10]. Runx2 is a master 
transcription factor that plays an essential role in osteoblast differentiation, regulating gene 
expression of bone matrix proteins and proteins important for bone mineralization [11]. 
Indeed, Runx2 knockdown has been shown to block bone formation and induce neonatal 
lethality in mice [12-14], whereas overexpression in vascular smooth muscle cells (VSMCs) 
induced a marked osteo-/chondrogenic phenotype [15]. Furthermore, overt calcification 
in diabetes and/or atherosclerosis was found to be preceded by Runx2 expression in the 
vasculature [16, 17], highlighting its role in vascular mineralisation and calcification.
Hepatocyte growth factor (HGF), a mesenchyme-derived cytokine with multiple 
biological effects, is a high affinity ligand for the c-Met receptor [18]. Elevated systemic 
levels and increased tissue expression of HGF and its receptor c-Met have been related to 
the progression of atherosclerosis and plaque development respectively [19, 20]. HGF/c-
Met signalling is known to promote osteogenic differentiation of bone marrow stromal cells 
[21] and previous studies from our group show that under specific micro-environmental 
conditions, such as hypercalcemia or hyperphosphatemia, HGF over-expression accelerates 
calcification in human VSMCs in vitro, via an up-regulation of osteogenic proteins, namely 
Runx2, ALP, Osteocalcin (OC), BMP2, and Osterix, an effect which can be blocked by inhibition 
of endogenous HGF/c-Met signalling [18]. In addition, we have demonstrated HGF/c-Met 
binding increased Akt phosphorylation, activation of Notch and its downstream target 
protein HES1, where the calcification process was subsequently attenuated in the presence 
of the Notch inhibitor DAPT, leading us to suggest that Notch/Hes1 signalling is essential for 
HGF-induced VSMC osteogenic differentiation [18].
Notch is a key signalling pathway in the physiological differentiation and cross-talk 
between different types of cells. Notch receptors (Notch1-4) and ligands are expressed in the 
vascular system, and activation of these receptors results in the release of Notch intracellular 
domain (NICD) which translocate to the nucleus where it regulates several target genes, 
including HES1 [22]. Notch3 influences the phenotype and functions of VSMCs [23] and 
since we have demonstrated the activation of c-Met/Akt/Notch3 signalling in the osteogenic 
differentiation of VSMCs [18], we have proposed that c-Met signalling could represent a 
target in the prevention and/or treatment of vascular calcification, via activation of Akt and 
Notch3 signalling in vitro.
Glycosaminoglycans (GAGs) are components of the extracellular matrix and act as 
mediators of cellular signalling. Heparan sulfate (HS) is a highly sulfated GAG present in the 
extracellular matrix of almost all tissues, and is known to be critically implicated in regulating 
angiogenesis, inflammation, immunity and metastasis [24-26]. The biological effects of HS 
are known to be mediated by the variable sulfation pattern [27], thus HS oligosaccharides 
can mimic the former cellular processes in biological systems, and help overcome the 
complexity of the synthesis of HS mimetics [28, 29]. It has also been shown that HS mimics 
can inhibit HGF/c-Met interaction [30] and we recently established for the first time, the 
protective effect of a class of small molecule glycomimetics against endothelial dysfunction 
in vitro and ex vivo [31].
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Since endothelial dysfunction plays a key role in the pathogenesis of vascular disease, 
including the development of atherosclerotic plaque and vascular calcification, and the 
predicted ability of glycomimetics to interrupt HGF/c-Met signalling, the aim of the study 
was to evaluate whether small molecule glycomimetics inhibit vascular calcification in an 
in vitro human VSMC model. To the best of our knowledge, studies on the potential of small 
molecule HS mimetics in the protection against VSMC calcification have not yet been studied.
Materials and Methods
Explanting and culture of human VSMCs
VSMCs were obtained by tissue explantation using human popliteal arterial sections as previously 
described [32]. The tissue samples were collected from patients with peripheral vascular disease following 
below knee amputation, with informed consent and full ethical approval from the NRES Committee North 
West-Lancaster (REC reference; 14/NW/1062). After cleaning, the adventitia was removed and medial 
tissue was dissected into 1 mm squares and incubated in smooth muscle cell growth medium (Cat. No. 
C-22162; PromoCell GmbH, Heidelberg, Germany). The medium was changed every 2 days and human 
VSMCs were used between passages 2 and 4.
Induction of calcification and treatments
β-glycerophosphate (β-GP) has been reported to induce calcification in cultured VSMCs [33] and 
is commonly utilised in a well-established in vitro model of vascular calcification for functional and 
mechanistic studies. In the present study, VSMCs were cultured in the regular growth media (PromoCell 
GmbH, Heidelberg, Germany). At 80% confluence, the cells were switched to DMEM containing 10% fetal 
bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 2.6 mM CaCl
2
 and 5 mM β-GP, to induce 
mineralization. Starting from the first day of induction, 10 µM of each test compound was added and the 
media was changed every 3 days.
Alizarin red staining
At day 21, VSMCs in 6-well plates were washed 3 times with PBS and fixed in 4% formaldehyde for 
10 minutes. After washing, the cells were incubated with 2%, wt/vol alizarin red S (pH 4.2), as previously 
described [18, 32, 34]. The stain was eluted by incubation with 10% formic acid (1ml/well) with shaking 
for 5 minutes and transferred to a 96-well plate where the absorbance was read at 414 nm on a microplate 
reader (BioTek). 10% formic acid was used as a blank.
Calcium deposition quantification
VSMCs were seeded into 12-well plates and were incubated in osteogenic medium with and without 
the glycomimetics C1-C4 for 14 days. The cells were washed with cold PBS and the calcium was eluted with 
0.6 M HCl for 24 h. The calcium content in the supernatant was then determined colorimetrically using a 
reagent kit purchased from Abcam (Cat No. ab102505) where the free Ca2+ forms a chromogenic complex 
with O-cresolphthalein. The optical density of the chromogen was measured at 575 nm on a microplate 
reader (BioTek) and the data were normalized to total protein content, as determined using a bicinchoninic 
acid (BCA) protein assay (Pierce Biotechnology).
Alkaline Phosphatase (ALP) Assay
To test the effect of small molecule glycomimetics on ALP activity, VSMCs were cultured in 12-well 
plates with osteogenic medium and treated with 10 µM C1-C4. At days 4, 7 and 10, the cells were washed 
with PBS and lysed with 1% Triton X-100 in PBS. The lysate was centrifuged and total cellular proteins 
were quantified. Twenty µg protein was used to assay ALP activity as previously described [34]. The results 
were normalized to total protein and an enzyme unit is the number of nmol of nitrophenol formed per µg of 
cellular protein per minute.
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Quantitative real-time PCR 
(qRT-PCR)
On day 7, cells in 6-well 
plates were harvested for 
isolation of RNA using Trizol 
reagent (Invitrogen). RNA 
was quantified and reverse 
transcribed into cDNA 
using SuperScript II reverse 
transcriptase and oligo 
deoxythymidine primers 
(Sigma) on Surecycler 
8800 thermocycler (Agilent 
Technologies). The first strand 
cDNA was amplified using SYBR 
Green master mix (Bioline, UK) 
in a total volume of 20 µL with the primer sets outlined in Table 1. The samples were amplified for 40 cycles 
with a denaturation at 95 °C for 30 sec, annealing for 60 sec and extension for 30 sec at 72 °C. Melting curves 
and agarose gel electrophoresis were used to assess quality of the PCR products. The results were analysed 
using the 2-ΔΔCt method and data normalized to GAPDH.
Western blot analysis
Western blot analysis was used to determine the effects of glycomimetics and inhibitors of Notch and 
c-Met on c-Met phosphorylation, as well as Notch3 and HES1 protein levels in VSMCs. Cells were cultured 
in osteogenic medium with and without 10 µM C2, 10 µM C4, 1 µM DAPT (N-[N-(3, 5-Difluorophenacetyl-
L-alanyl)]-S-phenylglycine t-butyl ester; Sigma-D5942), or 1 µM crizotinib (c-Met inhibitor, Sigma-PZ0191) 
for 21 days. The cells were harvested and homogenized in RIPA buffer supplemented with proteinase/
phosphatase inhibitors. Total proteins were quantified and samples were separated using 10% SDS-
polyacrylamide gel electrophoresis (SDS/PAGE) and then transferred to PVDF membrane. Blots were 
blocked and incubated overnight at 4 °C with rabbit antibodies for phospho-c-MetTyr1349 (ab68141), c-Met 
(sc-161), Notch3 (sc-5593), HES-1 (ab71559), or α-tubulin (ab7291). After incubation with the secondary 
antibodies, the blots were developed with ECL reagent (Amersham Pharmacia Biotech). Protein signals 
were analysed using ImageJ (version 1.32j, NIH, http://rsb.info.nih/ij/).
Statistical analysis
Data were analysed using GraphPad Prism 5 (GraphPad Software, San Diego, USA). The results were 
compared using a one-way analysis of variance (ANOVA) test followed by Tukey’s post-hoc analysis. 
The obtained data were expressed as mean ± standard error of the mean and P value less than 0.05 was 
considered significant.
Statement of Ethics
The tissue samples were collected from patients with full informed consent of the participants and full 
ethical approval from the NRES Committee North West-Lancaster (REC reference; 14/NW/1062).
Results
Small molecule glycomimetics inhibit β-GP-induced calcification in human VSMCs
The effect of small molecule glycomimetics (C1-C4) on β-GP-induced calcification was 
evaluated using alizarin red staining (imaging and quantifying the eluted stain), and by 
calcium assays. Alizarin red staining, performed on day 21, showed that all 4 glycomimetics 
inhibited β-GP-induced granular calcified nodule formation (Fig. 1A). This result was 
validated by measuring the absorbance of the eluted alizarin red stain, with glycomimetic-
treated VSMCs demonstrating a significant reduction in alizarin red staining compared to 
Table 1. Primers used for qRT-PCR
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untreated VSMCs (P<0.001) to control levels (Fig. 1B). These data were further confirmed 
using a calcium content assay, where β-GP treated human VSMCs showed a significant 
increase in calcium content at day 14 (P<0.001), an effect that was significantly decreased to 
untreated control levels by all tested compounds (P<0.001; Fig. 1C).
Small molecule glycomimetics prevent β-GP-induced ALP activity and expression in human 
VSMCs
ALP activity and mRNA abundance was measured as an early marker of osteogenic 
differentiation to further investigate the effect of the glycomimetics on β-GP-induced 
calcification. At days 4, 7 and 10, treatment with β-GP induced a significant increase in 
ALP activity in human VSMCs (P<0.001; Fig. 2A). ALP mRNA abundance was significantly 
up-regulated after 7 days of β-GP treatment (P<0.001; Fig. 2B), which was significantly 
attenuated (P<0.001) to untreated control levels after treatment with either C1, C2, C3 or C4.
Fig. 1. Small molecule 
glycomimetics inhibit 
β-GP-induced calci-
fication in human 
VSMCs. (A & B) 
Alizarin red staining 
showing inhibition 
of calcification by 
the small molecule 
glycomimetics (C1-
C4) in human VSMC 
treated with 5 mM 
β-GP for 21 days (C) 
C1-C4 reduce β-GP-
induced calcium 
deposition at day 14. 
Results are mean ± 
SEM; n = 6–8, and 
experiments were 
repeated at least three 
times independently. 
***P<0.001. β-GP, 
β-glycerophosphate; 
ns, non-significant.
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Small molecule glycomimetics prevent β-GP-induced transdifferentiation of human VSMCs 
into osteoblast-like cells
To assess the effects of the 4 glycomimetics on pathways involved in β-GP-induced 
osteogenic differentiation of human VSMCs, the levels of specific mRNAs involved in in this 
process were investigated. BMP-2, RUNX2 (CBFA1; Core-binding factor α1), MSX2 and OPN 
mRNA abundance were significantly up-regulated in human VSMCs following 7 days of 
treatment with β-GP (Fig. 3).
In contrast, glycomimetics C1-C4 significantly reduced the mRNA abundance of BMP-
2 (P<0.001), RUNX2 (P<0.001), MSX2 (P<0.05) and OPN (P<0.01) compared to the β-GP-
induced cells (Fig. 3). In particular, C1 and C2 produced a more marked down-regulation of 
MSX2 (P<0.01; Fig. 3C) compared to C3 and C4 (P<0.05).
Small molecule glycomimetics downregulate c-Met/Notch3/HES1 signalling in β-GP-
induced human VSMCs
Our previous studies have shown that c-Met/Akt/Notch3 signalling is activated during 
VSMC calcification in vitro [18]. Therefore, we investigated the effect of C1-C4 small molecule 
glycomimetics on c-Met/Notch3/HES1 regulation after 21 days of β-GP-induced calcification.
Given that previous data showed no significant differences between all four compounds 
in terms of osteogenic differentiation, only C2 and C4 were selected for further testing. β-GP 
significantly increased c-MetTyr1349 phosphorylation (P<0.01; Fig. 4A) in human VSMCs at day 
21, whereas it was significantly reduced after the addition of either C2, C4, crizotinib (the 
c-Met inhibitor) or DAPT (Notch inhibitor) (P<0.01).
Fig. 2. Small molecule glycomimetics prevent β-GP-induced ALP activity and mRNA abundance in human 
VSMCs. (A-C) ALP activity was determined at days 4, 7 and 10. Glycomimetics C1-C4 significantly inhibit 
β-GP-induced ALP activity. (D) ALP mRNA abundance was significantly up-regulated after 7 days of β-GP 
treatment and was inhibited by C1-C4. Results are mean ± SEM; n = 6-10, and experiments were repeated at 
least three times independently. ***P<0.001. β-GP, β-glycerophosphate; ns, non-significant.
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The effect of C2, C4, crizotinib and DAPT on Notch3 levels in β-GP-induced human VSMCs 
at day 21 was determined. β-GP significantly up-regulated Notch3 protein levels (P<0.001), an 
effect that was markedly reversed by C2 (P<0.001), DAPT (P<0.001) and crizotinib (P<0.05), 
but not with C4 treatment. DAPT significantly inhibited Notch3 expression (P<0.05) when 
compared with untreated control cells (Fig. 4B), supporting our previously published data 
[18].
Fig. 3. Small molecule 
glycomimetics inhibit β-GP-
induced osteoinductive 
signalling in human VSMCs. 
Glycomimetics C1-C4 
reduce mRNA abundance 
of (A) BMP-2, (B) RUNX2, 
(C) MSX2 and (D) OPN in 
VSMCs treated with β-GP 
for 7 days. Results are 
mean ± SEM; n = 6, and 
experiments were repeated 
at least three times 
independently. *P<0.05, 
**P<0.01, ***P<0.001. 
β-GP, β-glycerophosphate; 
ns, non-significant.
Fig. 4. Small molecule 
glycomimetics down-
regulate c-Met/Notch3/
HES1 signalling in 
β-GP-induced human 
VSMCs. (A) c-MetTyr1349 
phosphorylation was 
significantly increased 
after treatment with β-GP 
for 21 days which was 
significantly decreased 
by C2, C4, crizotinib and 
DAPT. (B, C) C2 and DAPT 
significantly decreased 
Notch3 (B) and HES-1 
(C) protein expression in 
VSMCs treated with β-GP 
for 21 days. Results are 
mean ± SEM; n = 6. *P<0.05, 
**P<0.01, ***P<0.001. 
β-GP, β-glycerophosphate; 
ns, non-significant.
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HES1 protein expression was significantly up-regulated (P<0.05) at day 21 following 
β-GP treatment (Fig. 4C) which was significantly downregulated after C2 and DAPT 
treatment (P<0.001), whereas C4 and crizotinib exerted a non-significant effect. When 
compared with the untreated control VSMCs, DAPT significantly (P<0.01) decreased HES1 
protein expression (Fig. 4C).
Glycomimetic modulation of the H/HS interaction with HGF
Based on the downstream knockdown of c-Met phosphorylation with glycomimetics 
C2 and C4 in an analogous manner to the known c-Met inhibitor, Crizotinib [35], possible 
binding modes for C2 and C4 upstream of c-Met were proposed. The c-Met receptor has both 
an intracellular kinase domain and an extracellular receptor binding domain as two potential 
binding sites [36]. Based on the polar nature of C2 and C4 and lack of hinge-binding motifs, it 
is highly unlikely that they cross the membrane but instead act at the extracellular receptor 
level rather than directly with the kinase domain. HGF is a known c-Met receptor agonist and 
NK4 a known c-Met receptor antagonist [18]. Whether the glycomimetic interacts directly 
with HGF and prevents binding or acts as a receptor antagonist (like NK4) remains to be 
elucidated.  However, it would be unlikely for a simple small molecule to mimic a larger 
protein surface so effectively. In order to predict the binding possibilities of C2 and C4 to 
HGF, the docking program GOLD [37, 38] was used to generate the lowest energy binding 
poses, shown in Fig. 5. Both these binding poses, mimic the region that the known HGF-
binder, heparan sulfate binds to with good confidence. It would seem most likely that C2 and 
C4 mimic the binding event of HGF-H/HS and disrupt HGF from engaging with c-Met and 
activating downstream c-Met phosphorylation.
Discussion
Vascular calcification is a highly regulated process of reprogramming VSMC into osteo-/
chondrogenic phenotypes [39, 40] provoked by increased extracellular phosphate [41], but 
also induced under conditions of with inflammation (TNFa, IL6), oxidative stress elevated LDL 
cholesterol, aging (senescence and DNA damage) in combination with either osteoporosis, or 
atherosclerosis [4, 9, 42].. Use of high phosphorus and calcium levels in cell culture media is a 
well established in vitro model for the study of the osteogenic differentiation of VSMCs [43]. 
Fig. 5. Representative docking pictures of glycomimetic (A) C2 and (B) C4 in the HGF-heparan sulfate 
binding site (PDB: 1GMN).
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Indeed, increased serum levels of inorganic phosphate are believed to link bone turnover to 
vascular calcification and play a significant role in the development of VSMC calcification [44, 
45]. This role has been supported by studies where reducing hyperphosphatemia through 
treatment with phosphate-binding agents effectively prevented vascular calcification in 
mice [46] and chronic kidney disease patients [47].
In the present study, β-GP induced calcification of the human VSMCs, demonstrated by 
positive alizarin red staining and calcium deposition. It is well-known that β-GP releases 
inorganic phosphate and raises its concentration in the culture medium [33], therefore, this 
model was chosen for our investigation. Calcium deposition was assayed at day 14 and the 
findings were similar to those reported by Alesutan et al. in primary human aortic smooth 
muscle cells at the same time point, suggesting similarities between different vascular beds 
[48].
Interestingly, all 4 small molecule glycomimetics used in this study markedly inhibited 
β-GP-induced calcium deposition and VSMC calcification. The four glycomimetics are 
highly charged polar molecules with 3-4 sulfate groups and therefore, will have similar 
physicochemical properties. Furthermore, the molecular modelling demonstrates the 
similarity of interaction for the two key structures and may explain the similarity of activity 
demonstrated. Since β-GP induces calcification in an ALP-dependent manner [49], we 
assayed the effect of C1-C4 HS mimetics on both activity and gene expression of ALP. All small 
molecule glycomimetics inhibited the β-GP-induced increase in ALP activity at days 4, 7 and 
10, and ALP mRNA abundance at day 7. Since increased activity of ALP is an early marker 
of calcification, our findings support a potential role for small molecule glycomimetics in 
attenuation of VSMC mineralisation/calcification.
In the knowledge that vascular calcification is a complex process due to an elevated 
calcium phosphate product, and is known to involve an active transdifferentiation into 
osteoblast-like cells [50], the effect of C1-C4 glycomimetics on the expression of specific genes 
in osteoblastic and osteogenic cells were investigated. Multiple studies have demonstrated 
increased expression of osteoblastic and calcification markers such as BMP-2, Runx2, ALP 
and OPN in calcified valves and vessels [39, 51]. These findings were supported by in vitro 
studies showing up-regulated BMP-2, RUNX2, ALP and OPN in VSMCs subjected to elevated 
phosphate levels [48, 52, 53]. We hypothesized that down-regulating expression of these 
osteoblastic and calcification markers by the test glycomimetics mediate, at least in part, 
β-GP-induced vascular calcification. Here, β-GP-treated VSMCs exhibited a substantial 
increase in the mRNA abundance of BMP-2, RUNX2, MSX2 and OPN, an effect that was 
markedly prevented by C1-C4 glycomimetics.
BMP-2 is a crucial factor in the regulation of osteogenic differentiation and osteoblast 
proliferation. Like osteoblasts, VSMCs are derived from the mesenchymal precursor 
cells which can express and secrete BMP-2 [54] and has been implicated in promoting 
calcification of VSMCs in humans [7, 55, 56]. Pathological studies of calcified vessels have 
shown increased expression of BMP-2 and several downstream bone-related proteins [57, 
58]. A recent study by Sun et al. reported the role of endogenous BMP-2 and osteogenic 
differentiation in the process of vascular calcification [59]. BMP-2 accelerates phosphate 
uptake [7], and upregulates expression of Runx2 [9] and ALP [10]. Runx2 is an osteogenic 
transcription factor involved in the differentiation of osteo-/chondrogenic phenotype [60] 
and studies have demonstrated that Runx2 orchestrates the transformation of VSMC into 
osteoblast-like cells [61, 62] through regulating several dependent genes including ALP, OPN 
and other factors [63, 64]. Runx2 increases the expression of receptor activator of nuclear 
factor κB ligand (RANKL) leading to transdifferentiation of SMCs into osteoblast-like cells 
[65]. Elevated levels of extracellular phosphate have been reported to induce Runx2 and 
other osteoblastic differentiation factors [48].
In addition, BMP-2 induces Msx2 expression leading to osteogenic differentiation and 
mineralisation of VSMCs [54]. Msx2 is a homeodomain transcription factor that commits 
mesenchymal cells to osteogenesis, not to adipogenesis [66] and is responsible for 
differentiation and mineralisation of osteoblasts [67]. Experiments using a mouse model 
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of medial artery calcification showed activated gene expression of BMP-2 and Msx2 in the 
aortic adventitia [68, 69]. We and others [70, 71] have shown that Msx2 mediates the Notch 
signalling-induced osteogenic differentiation of VSMCs. Shimizu et al. also reported a cross-
talk between Notch and BMP-2 signalling in VSMCs, leading to enhanced activation of Msx2 
during vascular calcification [54]. Notch was also demonstrated to induce ALP activity in 
human aortic SMCs [70]. Hence, BMP-2 requires Notch signalling and the Notch/BMP-2-
induced Msx2 activation plays a role in VSMC calcification [54]. Therefore, modulation of 
BMP-2, Runx2 and Msx2 expression by small molecule glycomimetics in this study could 
represent a novel therapeutic direction for preventing vascular calcification.
Our previous work [18] revealed the role of c-Met/Akt/Notch3 signalling in the 
osteogenic differentiation of VSMCs, triggered by HGF. Therefore, we have investigated 
the possible involvement of c-Met/Notch3/HES1 in the protective role of small molecule 
glycomimetics against β-GP-induced vascular calcification. Notably, c-Met phosphorylation 
and HES1 protein expression were significantly increased in VSMCs treated with β-GP at 
day 21, which were significantly decreased by the glycomimetics. HES1 has been reported to 
stimulate Runx2 activity and osteogenesis [42]. The small molecule glycomimetics inhibited 
c-Met phosphorylation, and Notch3 and HES1 expression, suggesting that the c-Met/
Notch3/HES1 signalling pathway could play a role in their protective effect against VSMC 
calcification. Due to the highly polar nature of the glycomimetics, designed to mimic the HGF-
heparan sulfate binding interaction [31], an extracellular modulation of the ability of HGF to 
bind to c-Met has been proposed.
Conclusion
In summary, this is the first study demonstrating that these small molecule glycomimetics 
can attenuate VSMC calcification through decreasing calcium deposition, down-regulation of 
osteoblastic and calcification markers, and modulation of the c-Met/Notch3/HES1 signalling 
pathway (Fig. 6). However, further studies are required to better understand the role of 
c-Met/Notch3/HES1 signalling in mediating the protective effect of these glycomimetics 
against VSMC calcification. Our study may serve as a base for the development of a new drug 
for vascular calcification, for potential translation to the clinic.
Fig. 6. Schematic diagram 
demonstrating the protective 
effects of small molecule 
glycomimetics against phosphate-
induced osteogenic signalling and 
vascular calcification.
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